Top advances of the year: Pediatric oncology

Accelerated discovery and collaborative research continue to highlight the remarkable progress that has been made in the diagnosis and treatment of pediatric cancers. This manuscript highlights important discoveries on how precision oncology is being incorporated into the diagnosis and treatment of childhood cancer at the national level to identify promising new therapies using a tumor-agnostic approach. In addition, we have highlighted three articles that incorporate genomics and cell-free DNA to better classify, monitor and incorporate risk-based therapies for children with medulloblastoma. Finally, we highlighted the important role of monclonal antiobody therapy in the treatment of recurrent B-cell leukemia and newly diagnosed high-risk neuroblastoma.

Automated summary

This manuscript highlights the significant progress in the diagnosis and treatment of pediatric cancers, especially the application of precision oncology and tumor-agnostic approach. It also emphasizes the use of genomics and cell-free DNA in the treatment of medulloblastoma, as well as the important role of monoclonal antibody therapy in treating B-cell leukemia and neuroblastoma.